Aroa Biosurgery Ltd - Asset Resilience Ratio
Aroa Biosurgery Ltd (ARX) has an Asset Resilience Ratio of 12.13% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Aroa Biosurgery Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2025)
This chart shows how Aroa Biosurgery Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of Aroa Biosurgery Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Aroa Biosurgery Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ARX market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$11.56 Million | 12.13% |
| Total Liquid Assets | AU$11.56 Million | 12.13% |
Asset Resilience Insights
- Moderate Liquidity: Aroa Biosurgery Ltd has 12.13% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Aroa Biosurgery Ltd Industry Peers by Asset Resilience Ratio
Compare Aroa Biosurgery Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Inspire Medical Systems Inc
NYSE:INSP |
Medical Devices | 20.29% |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186 |
Medical Devices | 0.84% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Stratec SE
XETRA:SBS |
Medical Devices | 0.30% |
|
Duearity AB
ST:DEAR |
Medical Devices | 145.62% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
Annual Asset Resilience Ratio for Aroa Biosurgery Ltd (2001–2025)
The table below shows the annual Asset Resilience Ratio data for Aroa Biosurgery Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 13.00% | AU$12.87 Million ≈ $9.10 Million |
AU$98.94 Million ≈ $70.01 Million |
-3.84pp |
| 2024-03-31 | 16.84% | AU$17.16 Million ≈ $12.14 Million |
AU$101.88 Million ≈ $72.09 Million |
-14.39pp |
| 2023-03-31 | 31.23% | AU$34.07 Million ≈ $24.10 Million |
AU$109.07 Million ≈ $77.17 Million |
-14.25pp |
| 2022-03-31 | 45.48% | AU$47.62 Million ≈ $33.70 Million |
AU$104.71 Million ≈ $74.09 Million |
+43.50pp |
| 2021-03-31 | 1.99% | AU$1.45 Million ≈ $1.03 Million |
AU$73.12 Million ≈ $51.74 Million |
+0.84pp |
| 2020-03-31 | 1.14% | AU$944.72K ≈ $668.45K |
AU$82.54 Million ≈ $58.40 Million |
+1.12pp |
| 2019-03-31 | 0.03% | AU$9.60K ≈ $6.79K |
AU$37.96 Million ≈ $26.86 Million |
-0.23pp |
| 2018-03-31 | 0.26% | AU$37.00K ≈ $26.18K |
AU$14.30 Million ≈ $10.12 Million |
-0.31pp |
| 2017-03-31 | 0.57% | AU$37.00K ≈ $26.18K |
AU$6.52 Million ≈ $4.61 Million |
+0.02pp |
| 2016-03-31 | 0.55% | AU$35.00K ≈ $24.76K |
AU$6.36 Million ≈ $4.50 Million |
+0.08pp |
| 2015-03-31 | 0.47% | AU$35.00K ≈ $24.76K |
AU$7.51 Million ≈ $5.31 Million |
+0.05pp |
| 2014-03-31 | 0.42% | AU$35.00K ≈ $24.76K |
AU$8.41 Million ≈ $5.95 Million |
+0.04pp |
| 2013-03-31 | 0.37% | AU$35.00K ≈ $24.76K |
AU$9.36 Million ≈ $6.62 Million |
+0.05pp |
| 2012-03-31 | 0.32% | AU$35.00K ≈ $24.76K |
AU$10.93 Million ≈ $7.73 Million |
-0.11pp |
| 2011-03-31 | 0.43% | AU$35.00K ≈ $24.76K |
AU$8.07 Million ≈ $5.71 Million |
-0.25pp |
| 2010-03-31 | 0.68% | AU$35.00K ≈ $24.76K |
AU$5.13 Million ≈ $3.63 Million |
+0.64pp |
| 2009-03-31 | 0.04% | AU$35.00K ≈ $24.76K |
AU$83.08 Million ≈ $58.79 Million |
-0.01pp |
| 2008-03-31 | 0.05% | AU$35.00K ≈ $24.76K |
AU$71.60 Million ≈ $50.66 Million |
-5.03pp |
| 2007-03-31 | 5.08% | AU$4.50 Million ≈ $3.18 Million |
AU$88.53 Million ≈ $62.64 Million |
-7.98pp |
| 2005-03-31 | 13.06% | AU$2.56 Million ≈ $1.81 Million |
AU$19.60 Million ≈ $13.87 Million |
-18.74pp |
| 2004-03-31 | 31.80% | AU$4.91 Million ≈ $3.47 Million |
AU$15.44 Million ≈ $10.93 Million |
-6.39pp |
| 2003-03-31 | 38.19% | AU$4.63 Million ≈ $3.28 Million |
AU$12.12 Million ≈ $8.58 Million |
-17.87pp |
| 2002-03-31 | 56.06% | AU$6.93 Million ≈ $4.90 Million |
AU$12.37 Million ≈ $8.75 Million |
+50.57pp |
| 2001-03-31 | 5.49% | AU$760.00K ≈ $537.75K |
AU$13.85 Million ≈ $9.80 Million |
-- |
About Aroa Biosurgery Ltd
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more